Could a simple blood test someday help spot blocked heart arteries before symptoms get worse? A new analysis pulls together data from nearly 3,900 people with confirmed coronary artery disease to see how well tiny molecules in the blood, called microRNAs, can flag the condition. The results are promising but not yet ready for your doctor's office. Pooled sensitivity was 0.777, meaning the test correctly identified about 78 out of 100 people who had the disease. Pooled specificity was 0.832, meaning it correctly ruled out about 83 out of 100 people who did not. Overall accuracy, measured by a statistic called SROC-AUC, was 0.872. When researchers combined several microRNAs into a panel, accuracy rose to 0.901, compared with 0.868 for a single microRNA. That suggests a multi-marker approach may work better. But there is a big caveat: the studies were very inconsistent, with a heterogeneity score of 92.1 percent, meaning results varied widely from one study to another. The authors say these markers are still investigational and need prospective validation with standardized protocols before they could be used in clinical care. No safety issues were reported, but the analysis did not track side effects.
Circulating microRNAs show moderate diagnostic accuracy for coronary artery disease, multi-miRNA panels outperform single markersBlood markers show promise for spotting heart artery disease
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This meta-analysis assessed the diagnostic accuracy of circulating microRNAs (miRNAs) for coronary artery disease in 3879 patients with angiography-confirmed disease. The authors pooled data from multiple studies to estimate sensitivity, specificity, and summary receiver operating characteristic (SROC) area under the curve (AUC).
Pooled sensitivity was 0.777 (95% CI 0.737-0.816) and pooled specificity was 0.832 (95% CI 0.801-0.862). The overall SROC-AUC was 0.872. When comparing panel designs, multi-miRNA panels achieved an AUC of 0.901, higher than the 0.868 AUC for single miRNAs.
The authors reported substantial heterogeneity for sensitivity (I²=92.1%; τ²=0.738). They noted that prospective validation with standardized protocols is required before clinical deployment. No safety data, adverse events, or tolerability outcomes were reported, as expected for a diagnostic accuracy review.
These findings suggest that circulating miRNAs have moderate-to-good diagnostic accuracy for CAD and may serve as investigational complementary biomarkers. However, the high heterogeneity and lack of prospective validation mean they are not ready for routine clinical use.
How this fits prior evidence
This meta-analysis extends prior coverage of non-invasive CAD diagnostics, such as AI-enhanced CCTA showing 0.823 sensitivity for hemodynamically significant disease. The pooled sensitivity of 0.777 and specificity of 0.832 for circulating miRNAs are in a similar range, but the SROC-AUC of 0.872 and the higher AUC of 0.901 for multi-miRNA panels suggest a potential complementary role. Unlike imaging advances that reduce radiation dose or improve procedural outcomes, this biomarker approach remains investigational and requires prospective validation.
Common questions
Is a panel of multiple microRNAs better than a single one?
Yes, according to this analysis. Multi-miRNA panels had an accuracy score of 0.901, compared with 0.868 for single microRNAs. That suggests combining several markers may improve detection, though the studies varied widely and more research is needed.
Can I get this test from my doctor now?
No. The authors say circulating microRNAs are investigational complementary biomarkers and not ready for clinical deployment. They require prospective validation with standardized protocols first. If you have concerns about coronary artery disease, talk to your doctor about proven testing options.
What are the side effects or risks of this test?
This analysis did not report any adverse events, serious adverse events, or discontinuations. Since it is a blood test, typical risks would be minimal, but the study did not track safety. Always discuss any test with your healthcare provider.
More on Coronary Artery Disease
View Original Abstract ↓
Bivalirudin reduces in-hospital major bleeding and 30-day mortality in patients with acute coronary syndrome
Bivalirudin shows lower bleeding risks than heparin for heart patients
Related in Cardiology
From Other Specialties
